Last reviewed · How we verify
CAIV-T
CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.
CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses. Used for Seasonal influenza prevention in children and adults.
At a glance
| Generic name | CAIV-T |
|---|---|
| Also known as | 0.2 mL, by nebulizer, FluMist |
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CAIV-T (Cold-Adapted Influenza Vaccine - Trivalent) uses temperature-sensitive, live attenuated influenza virus strains that replicate efficiently in the cooler upper respiratory tract but are restricted in replication in warmer lower respiratory and systemic tissues. This approach induces both local mucosal immunity (IgA) and systemic immunity (IgG), providing broader and more durable protection compared to inactivated vaccines. The vaccine covers influenza A (H1N1 and H3N2) and influenza B strains.
Approved indications
- Seasonal influenza prevention in children and adults
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
- Myalgia
Key clinical trials
- Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) (PHASE2)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults (PHASE3)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) (PHASE3)
- Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age (PHASE3)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older (PHASE2)
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants (PHASE1)
- Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma (PHASE1)
- A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAIV-T CI brief — competitive landscape report
- CAIV-T updates RSS · CI watch RSS
- MedImmune LLC portfolio CI